Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...